Pharmaceutical giant Merck announced Monday that its experimental oral medication achieved impressive results in advanced clinical testing, slashing harmful cholesterol levels by 64.6 percent.
The company revealed the late-stage trial outcomes as it searches for its next major commercial breakthrough in the competitive pharmaceutical market.
The oral treatment represents a significant development in cholesterol management, potentially offering patients a new option for controlling dangerous cholesterol levels that contribute to heart disease and other cardiovascular conditions.
